, Tracking Stock Market Picks
Enter Symbol:
Rating: GPRO
Mkt Outperform $21

Gopro Inc. (NASDAQ: GPRO) rated to Mkt Outperform with price target $21 by JMP Securities

Thursday,  Jan 14, 2016  10:25 AM ET by Betsy O'Brien Harrison

JMP Securities rated Gopro
Inc. (NASDAQ: GPRO) to Mkt Outperform with price target $21.

Gen-Probe Inc. is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing (NAT) products used for the clinical diagnosis of human diseases and for screening donated human blood. Using its patented NAT technology, Gen-Probe has received FDA approvals for more than 40 products that detect a wide variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy